Clinical Trial: Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07732348) titled 'Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI' on July 24.

Brief Summary: This study compares two medications used to prevent a premature hormone surge (LH surge) during controlled ovarian stimulation for in vitro fertilization (IVF). The standard approach uses an injectable GnRH antagonist (ganirelix or cetrorelix), given as a daily injection under the skin. This study evaluates linzagolix, an oral GnRH antagonist already approved for uterine fibroids and endometriosis, used here for the first time in ovarian stimulation (off-label use).

Women undergoing IVF/ICSI at CENTRO ...